Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib Addition to Neoadjuvant Letrozole in HR+/HER2- Breast Cancer
NCT05809024Phase 4Recruiting
- Sponsor
- Chengdu Yongsheng Biological Technology
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dalpiciclib in breast cancer, sponsored by Chengdu Yongsheng Biological Technology. Started Mar 2023; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05809024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809024.